Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala
Upcoming SlideShare
Loading in...5
×
 

Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala

on

  • 86 views

Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala

Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala

Statistics

Views

Total Views
86
Views on SlideShare
85
Embed Views
1

Actions

Likes
0
Downloads
1
Comments
0

1 Embed 1

http://www.bananaip.com 1

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala Presentation Transcript

    • Biotechnology and IP By Dr. Kalyan Kankanala Blog: www.bananaip.com/sinapse-blog
    • US Patent Law and Biotechnology
    • Overview • Article 1 Section 1 Clause 8 • Quid Pro Quo • Incentives • Title 35 • www.uspto.gov • www.fedcir.gov
    • Patentability requirements • Patentable subject matter • Utility • Novelty • Nonobviousness • Specification
    • INVENTIONS Subject Matter Usefulness Novelty Non-obviousness Specification PATENTS Kalyan’s Patent Filter Model
    • Patentable Subject Matter • Section 101 - Process, machine, manufacture, composition of matter and Improvements • Funk Bros. v. Kalo • Diamond v. Chakrabarty • Pioneer Hibebred v. J.E.M. Arguments and Issues
    • Funk Bros • Rhizobium bacteria • Innoculum of mutually inhibiting bacteria • Is it a product of nature?
    • Chakrabarty's case • Psuedomonas bacteria • Four different plasmids inserted. • Is it a product of Nature?
    • Utility • Current • Substantial • Credible • Brenner v. Manson • Gene/protein sequences
    • Novelty • Section 102 • Known or used • Patented or published • Public use or On sale • Abandoned • Foreign Priority • Patented in another country
    • Novelty • Derived • Suppressed or Concealed • Diligence • Single prior art reference • Isolated or purified- activity • Hybritech v. Monoclonal
    • Nonobviousness • Scope of prior art • Differences- invention and prior art • Level of ordinary skill • Secondary Indicia • At the time of conception • Obvious to try
    • Hybritech v. Monoclonal • immunometric assays using monoclonal antibodies
    • Prior Art • a. Kohler and Milstein's Nobel Prize-Winning Work for Producing Monoclonal antibodies in vitro; • b. The Work of Drs. Oi and Herzenberg, in which they used monoclonal antibodies to "map" epitopes or determine the number and location of different antibody binding sites on a known quantity of IgE antigen by attaching to it an antibody bound to a carrier and exposing that antigen to other monoclonal antibodies; • c. The Frankel Article that disclosed Monoclonal Antibodies Having Affinities of 109 liters/mole; and • d. Articles "Predicting" Widespread Use of Monoclonal antibodies.
    • In re Deuel: • Isolated and purified DNA and cDNA sequences encoding heparin-binding growth factors ("HBGFs")
    • Prior Art • Bohlen's patent application disclosed a group of protein growth factors designated as heparin-binding brain mitogens ("HBBMs") useful in treating burns and promoting the formation, maintenance, and repair of tissue, particularly neural tissue. Bohlen determined the first 19 amino acids of the proteins' N- terminal sequences, which were found to be identical for human and bovine HBBMs. He provided no teachings concerning DNA or cDNA coding for HBBMs in his application.
    • Prior Art • Maniatis described a method of isolating DNAs or cDNAs by screening a DNA or cDNA library with a gene probe. The reference outlined a general technique for cloning a gene but did not describe how to isolate a particular DNA or cDNA molecule.
    • Recent Developments • KSR Vs. Teleflex • In re Kubin
    • Specification • Written Description • Enablement • Best Mode • Claims • Object: Notice and Dissemination
    • Example • A stent coated with taxol for "treating or preventing recurrent stenosis. • Prior ArtStents Existing • Taxol known for Tumor treatment by angiogenesis • Article - Re-stenosis dangers and need for a treatment - suggests various options
    • Have a nice day For more information: www.bananaip.com www.bananaip.com/sinapse-blog Email: contact@bananaip.com